Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Up 6.1% in January

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 78,800 shares, an increase of 6.1% from the January 15th total of 74,300 shares. Based on an average trading volume of 130,700 shares, the short-interest ratio is currently 0.6 days. Currently, 1.5% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets lowered their price objective on Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Monday, December 16th.

Institutional Trading of Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Citadel Advisors LLC bought a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned 0.56% of Alzamend Neuro as of its most recent SEC filing. Institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Price Performance

Shares of NASDAQ ALZN opened at $1.09 on Tuesday. The business’s 50-day simple moving average is $1.17 and its 200-day simple moving average is $1.63. Alzamend Neuro has a 52 week low of $1.05 and a 52 week high of $15.06.

Alzamend Neuro (NASDAQ:ALZN) last announced its earnings results on Wednesday, December 11th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($2.38) by $1.98. Equities analysts forecast that Alzamend Neuro will post -1.68 earnings per share for the current year.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.